Clinical Trial Update: Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pasireotide LAR for prevention of lymphocele after axillary lymph node dissection in breast cancer; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Alliance Pour La Recherche en Cancerologie | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED